In a new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day Dexcom G7 integrated continuous glucose monitor (CGM) in adults with diabetes. Click here to read the article now .
The study enrolled 130 adults at six centers in the U.S. with either type 1 (87%) or type 2 diabetes on MDI (6%) or basal insulin only (7%) and analyzed CGM-venous (YSI) blood matched pairs (20,310), with participants using the 15-day Dexcom G7 CGM device.
Satish Garg, MD , from the University of Colorado Denver and Editor-in-Chief of Diabetes Technology & Therapeutics, and coauthors, reported that “The device exceeded iCGM performance goals and user experiences were broadly positive. No serious adverse events were reported.”
Accuracy evaluations included the mean absolute relative difference (MARD), which was 8.0%. This is the lowest reported MARD in a study designed to the U.S. Food and Drug Administration’s iCGM criteria.
“We conclude that the Dexcom 15-day G7 CGM is accurate and safe for use up to 15.5 days in adults with diabetes with a 27-minute warm-up,” stated the investigators.
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD , University of Colorado Denver, Barbara Davis Center for Diabetes, the Journal covers breakthrough technologies and new therapeutic drug classes, behavioral aspects and approaches to diabetes care, and the latest advancements and applications of new and emerging technologies including continuous glucose monitoring, alternate insulin delivery methods, artificial pancreas, telemedicine and computerized case management, new insulins with ultra-rapid onset of action, and detection and prevention of hypoglycemia. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) .
About Mary Ann Liebert, Inc., a Sage Company
Mary Ann Liebert, Inc. is a global media company dedicated to publishing and delivering impactful peer-reviewed research in biotechnology & life sciences, specialized clinical medicine, public health and policy, and technology & engineering. Since its founding in 1980, the company has focused on providing critical insights and content that empower researchers and clinicians worldwide to drive innovation and discovery.
Diabetes Technology & Therapeutics
Experimental study
People
Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes
20-Mar-2025